-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Parkinson's disease (PD) is a common neurological disease that usually occurs after 60 years of age, which seriously affects the quality of life of patients and has a high disability rate
.
According to statistics, there are currently about 5 million Parkinson's disease patients in the world, and about half of them are in China
Parkinson's disease (PD) is a common neurological disease, which usually starts after 60 years of age, which seriously affects the quality of life of patients and has a high disability rate
This live broadcast specially invites Professor Zhang Baorong, a distinguished professor of Zhejiang University Qiushi, a doctoral supervisor, the director of the Department of Neurology and the director of the teaching and research section of the Second Affiliated Hospital of Zhejiang University School of Medicine, the director of the Department of Neurology of the First Affiliated Hospital of Dalian Medical University, and the neurology credits of the Chinese Medical Association.
Professor Liang Zhanhua, member of the Parkinson and Movement Disorders Group, and member of the Amyotrophic Lateral Sclerosis Collaborative Group, gave live lectures on the topics of " Guidelines for the Diagnosis and Treatment of Parkinson's Disease" and "Talking about the Diagnosis and Treatment of Early-onset Parkinson's Disease in Combination with the New Guidelines " Made a professional introduction
.
Dr.
This live broadcast specially invites Professor Zhang Baorong, a distinguished professor of Zhejiang University Qiushi, a doctoral supervisor, the director of the Department of Neurology and the director of the teaching and research section of the Second Affiliated Hospital of Zhejiang University School of Medicine, the director of the Department of Neurology of the First Affiliated Hospital of Dalian Medical University, and the neurology credits of the Chinese Medical Association.
The latest Parkinson's disease diagnosis and treatment guidelines effectively guide the diagnosis
The latest Parkinson's disease diagnosis and treatment guidelines effectively guide the diagnosisProfessor Zhang Baorong, Qiushi Distinguished Professor of Zhejiang University, Ph.
D.
Supervisor, Director of the Department of Neurology and Director of the Teaching and Research Section of the Second Affiliated Hospital of Zhejiang University School of Medicine, gave a detailed interpretation of the "Guidelines for the Treatment of Parkinson's Disease in China (Fourth Edition)" , Professor Zhang He gave a general introduction to Parkinson's disease.
He pointed out that Parkinson's disease is a common movement disorder.
There are about 6 million patients with Parkinson's disease worldwide.
It is estimated that by 2030, the number of patients with Parkinson's disease will reach 9 million worldwide; and more than 50% worldwide Of Parkinson’s disease patients in China, China is facing a rapid aging of the population, leading to an increase in the number of Parkinson’s disease patients.
The prevalence rate of people over 65 in China is 1.
7%.
It is estimated that by 2030, China’s Parkinson’s disease patients will reach 5 million.
Seriously affect the quality of life of Chinese elderly patients
.
D.
Supervisor, Director of the Department of Neurology and Director of the Teaching and Research Section of the Second Affiliated Hospital of Zhejiang University School of Medicine, gave a detailed interpretation of the "Guidelines for the Treatment of Parkinson's Disease in China (Fourth Edition)" , Professor Zhang He gave a general introduction to Parkinson's disease.
He pointed out that Parkinson's disease is a common movement disorder.
There are about 6 million patients with Parkinson's disease worldwide.
It is estimated that by 2030, the number of patients with Parkinson's disease will reach 9 million worldwide; and more than 50% worldwide Of Parkinson’s disease patients in China.
China is facing a rapid aging of the population, leading to an increase in the number of Parkinson’s disease patients.
The prevalence rate of people over 65 years old in China is 1.
7%.
It is estimated that by 2030, China’s Parkinson’s disease patients will reach 5 million.
Seriously affect the quality of life of Chinese elderly patients
.
Interpretation
Since China launched the first edition of the Parkinson’s disease treatment guidelines in 2006, the fourth edition has been updated in 2020.
The new version of the guidelines covers 7 major aspects and can effectively guide the treatment of Parkinson’s disease
.
In the treatment principle of Parkinson's disease, the multidisciplinary treatment model is put forward, and the content that emphasizes the importance of whole-process management is of positive significance for the treatment of Parkinson's disease
Since China launched the first edition of the Parkinson’s disease treatment guidelines in 2006, the fourth edition has been updated in 2020.
Professor Zhang Baorong introduces Parkinson's disease treatment guidelines
Professor Zhang Baorong introduced the guidelines for the treatment of Parkinson's disease Professor Baorong Zhang introduced the guidelines for the treatment of Parkinson's diseaseEarly-onset Parkinson's disease needs prompt treatment
Early-onset Parkinson's disease needs prompt treatmentFirst Affiliated Hospital of Dalian Medical University, Department of Neurology, director of the Chinese Medical Association neuropathy credits Parkinson's disease and movement disorders study group members, Professor amyotrophic lateral sclerosis collaborative group members Liang Hua battle against introduced progress in diagnosis and treatment of early-onset Parkinson's disease, Professor Leung Point out that the age of onset is earlier than 50 years old, which is called early-onset Parkinson's disease
.
This type has the following characteristics: early age of onset, long course of disease, large clinical heterogeneity, relatively atypical symptoms, easy to be overlooked and misdiagnosed; although it responds well to low-dose levodopa preparations, it is more prone to motor complications , More attention needs to be paid to the need for individualized treatment and management
First Affiliated Hospital of Dalian Medical University, Department of Neurology, director of the Chinese Medical Association neuropathy credits Parkinson's disease and movement disorders study group members, Professor amyotrophic lateral sclerosis collaborative group members Liang Hua battle against introduced progress in diagnosis and treatment of early-onset Parkinson's disease, Professor Leung Point out that the age of onset is earlier than 50 years old, which is called early-onset Parkinson's disease
The pathogenesis of early-onset Parkinson's disease is mainly the interaction of genetic factors and environmental factors.
Professor Liang Zhanhua's live teaching scene
Liang Hua war Liang Hua battle professor teaching broadcast live professor teaching broadcast live
Director Mao Zhiqi presided over the meeting and provided answers
Director Mao Zhiqi presided over the meeting and carried out the answer work Director Mao Zhiqi presided over the meeting and carried out the answer work
About "Blue Handkerchief Public Welfare Project"
About "Blue Handkerchief Public Welfare Project""Blue Handkerchief Public Welfare Project"-Parkinson’s Disease Medical Development and Patient Care Special Action Through a series of activities such as science popularization, doctor training, free consultations, and patient assistance, we will increase public awareness of Parkinson's disease, improve the level of diagnosis and treatment of Parkinson's disease by grassroots doctors, and further reduce the misdiagnosis, missed diagnosis, and delayed treatment of Parkinson's disease patients in China.
Occurs, improving the quality of life of the Parkinson’s disease group
.
"Blue Handkerchief Public Welfare Project"-Parkinson’s Disease Medical Development and Patient Care Special Action Through a series of activities such as science popularization, doctor training, free consultations, and patient assistance, we will increase public awareness of Parkinson's disease, improve the level of diagnosis and treatment of Parkinson's disease by grassroots doctors, and further reduce the misdiagnosis, missed diagnosis, and delayed treatment of Parkinson's disease patients in China.
In 2021, the "Blue Handkerchief Public Welfare Project" has launched a number of popular science and free consultation activities
.
In order to encourage more doctors to participate in the project and provide more professional services for the public and Parkinson’s disease patients, the project integrates multiple resources such as Kuaishou, Metz Medicine, Miaoshou Doctors, Lianjia, local charities and government departments, to provide a group of doctors.
Provide professional support for the production of popular science content, the operation of doctors' personal accounts, the planning and organization of popular science/patient education activities, and the transformation of scientific research results
.
This public welfare activity was supported by a donation from Lipin Pharmaceutical .
Lipin Pharmaceutical is the first high-tech enterprise in Fujian Province that has passed the Sino-US GMP dual certification.
The company was founded in 2012 by a team of returned doctors led by national-level specially-appointed experts .
It has been committed to the research and development of Parkinson's disease for a long time and supports the training of young doctors.
.
Lipin has multiple core technology platforms such as innovative oral film technology platform, high-end sustained and controlled release formulation technology platform, innovative microsphere formulation technology platform, and solubilizing formulation technology platform.
The company's quality system is in line with international standards, and product quality has reached international standards .
Lisuo® developed and produced by the company is the only domestically produced, dual-batch pramipexole hydrochloride sustained-release tablet in China and the United States , providing patients with a more convenient and safer treatment plan .
Lipin Pharmaceutical is the first high-tech enterprise in Fujian Province that has passed the Sino-US GMP dual certification.
The company was founded in 2012 by a team of returned doctors led by national-level specially-appointed experts .
It has been committed to the research and development of Parkinson's disease for a long time and supports the training of young doctors.
.
Lipin has multiple core technology platforms such as innovative oral film technology platform, high-end sustained and controlled release formulation technology platform, innovative microsphere formulation technology platform, and solubilizing formulation technology platform.
The company's quality system is in line with international standards, and product quality has reached international standards .
Lisuo® developed and produced by the company is the only domestically produced, dual-batch pramipexole hydrochloride sustained-release tablet in China and the United States , providing patients with a more convenient and safer treatment plan .
Leave a message here
